Literature DB >> 22498427

Clinical outcomes of congenital diaphragmatic hernia without extracorporeal membrane oxygenation.

Yuen Shan Tam1, Hon Ming Cheung, Yuk Him Tam, Kim Hung Lee, Hugh Simon Lam, Terence Chuen Wai Poon, Pak Cheung Ng.   

Abstract

BACKGROUND: Neonatal extracorporeal membrane oxygenation (ECMO) is not available in Hong Kong.
OBJECTIVES: To document the survival of neonates with symptomatic congenital diaphragmatic hernia at birth, but without access to ECMO.
METHODS: Twenty-two patients diagnosed to have CDH within a ten year period (1999-2009) at Prince of Wales Hospital were systematically reviewed. CDH patients who presented after the neonatal period were excluded.
RESULTS: There were 17 neonates with symptomatic CDH at birth and the overall survival, including infants with multiple anomalies, was 14/17 (82%). 6 of 17 (35%) infants met the ECMO criteria and the survival rate for these serious cases was 4/6 (67%).
CONCLUSIONS: Our results are comparable with centers which provide ECMO and suggest that there may be only marginal benefit for using ECMO to improve survival. A territory-wide registry for documenting risk factors and outcomes would be important, especially in light of improving neonatal intensive care and survival.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22498427     DOI: 10.1016/j.earlhumdev.2012.03.002

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  2 in total

1.  Outcomes in the physiologically most severe congenital diaphragmatic hernia (CDH) patients: Whom should we treat?

Authors:  David W Kays; Saleem Islam; Joy M Perkins; Shawn D Larson; Janice A Taylor; James L Talbert
Journal:  J Pediatr Surg       Date:  2015-03-14       Impact factor: 2.545

2.  Congenital diaphragmatic hernia presenting with symptoms within the first day of life; outcomes from a non-ECMO centre in Denmark.

Authors:  Ulla Lei Larsen; Søren Jepsen; Thomas Strøm; Niels Qvist; Palle Toft
Journal:  BMC Pediatr       Date:  2020-05-07       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.